Sign In
Buy NPCE
$15.88
-0.410 (-2.52%)
At Close: Jun 03, 2026
NeuroPace to Participate in Upcoming Healthcare Conferences
08:00am, Thursday, 28'th Aug 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t
NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript
09:50pm, Tuesday, 12'th Aug 2025
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joel D. Becker - CEO, President & Director Patrick F.
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
06:26pm, Tuesday, 12'th Aug 2025
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago.
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
04:05pm, Tuesday, 12'th Aug 2025
-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
07:30am, Friday, 01'st Aug 2025
MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
10:00am, Wednesday, 02'nd Jul 2025
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to co
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
10:00am, Friday, 27'th Jun 2025
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to
NeuroPace Announces Strategic CFO Transition
04:05pm, Tuesday, 24'th Jun 2025
Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
03:42am, Tuesday, 24'th Jun 2025
LOS ANGELES , June 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NeuroPace, Inc. ("N
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
12:49pm, Monday, 23'rd Jun 2025
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors a
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
12:36pm, Sunday, 22'nd Jun 2025
LOS ANGELES--(BUSINESS WIRE)---- $NPCE--NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
10:00am, Sunday, 22'nd Jun 2025
NEW YORK , June 22, 2025 /PRNewswire/ -- APomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised t
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
02:55pm, Monday, 16'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
10:15am, Friday, 13'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are a
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect
10:00am, Friday, 13'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NA
